We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesQrons Inc

Qrons Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-07-02T21:06:06.525073Z
Market Cap
3.22M

Momentum Score

…

Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. The company was incorporated in 2016 and is based in Long Island City, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.21
Low
0.59
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
0.29M
ROCE
49.22%
Diluted EPS TTM
-0.10

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -0.73M -1.07M -0.66M -1.55M -3.93M
Net income -0.73M -1.07M -0.66M -1.55M -3.93M
Selling general administrative 0.44M 0.54M 0.30M 0.86M 2.99M
Gross profit - - - - 0.00M
Ebit - -0.80M -0.55M -1.52M -3.90M
Ebitda -0.60M -0.86M -0.61M -1.50M -3.91M
Operating income -0.63M -0.80M -0.55M -1.52M -3.90M
Interest expense 0.14M 0.21M 0.05M 0.04M 0.02M
Net interest income -0.14M -0.21M -0.05M -0.04M -0.02M
Income tax expense - - - - 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 0.63M 0.80M 0.55M 1.52M 3.90M
Cost of revenue - - - - 0.00M
Total other income expense net 0.03M -0.06M -0.06M 0.01M -0.01M
Net income from continuing ops -0.73M -1.07M -0.66M -1.55M -3.93M
Net income applicable to common shares - -1.07M -0.66M -1.55M -3.93M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 0.00M 0.04M 0.06M 0.12M 0.20M
Total liab 1.28M 1.14M 0.75M 0.63M 0.09M
Total stockholder equity -1.28M -1.10M -0.69M -0.51M 0.11M
Other current liab 0.36M 0.42M 0.18M 0.09M 0.04M
Common stock - 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -9.53M -8.80M -7.73M -7.07M -5.52M
Cash 0.00M 0.04M 0.06M 0.07M 0.14M
Total current liabilities 1.28M 1.14M 0.75M 0.63M 0.09M
Net debt 0.29M 0.18M 0.06M 0.01M -
Short term debt - - - 0.08M 0.03M
Short long term debt 0.29M 0.22M 0.12M 0.08M 0.03M
Total current assets 0.00M 0.04M 0.06M 0.12M 0.20M
Net tangible assets - -1.10M -0.69M -0.51M 0.11M
Accounts payable - 0.08M 0.04M 0.17M 0.02M
Non currrent assets other - - - 0.00M 0.00M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00M 0.00M 0.00M 0.00M 0.00M
Change to liabilities - 0.04M -0.08M 0.15M 0.01M
Net borrowings - 0.10M 0.11M 0.41M 0.41M
Total cash from financing activities 0.07M 0.10M 0.21M 0.47M 0.57M
Change to operating activities - - 0.06M -0.00M -0.04M
Net income -0.73M -1.07M -0.66M -1.55M -3.93M
Change in cash -0.03M -0.02M -0.01M -0.08M 0.09M
Begin period cash flow 0.04M 0.06M 0.07M 0.14M 0.06M
End period cash flow 0.00M 0.04M 0.06M 0.07M 0.14M
Total cash from operating activities -0.10M -0.12M -0.22M -0.55M -0.49M
Issuance of capital stock - 0.00M 0.10M 0.07M 0.57M
Change to netincome - 0.81M 0.43M 0.82M 3.45M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.06M 0.04M -0.03M 0.14M -0.02M
Stock based compensation 0.32M 0.66M 0.37M 0.76M -
Other non cash items 0.28M 0.19M 0.20M 0.87M 3.46M
Free cash flow -0.10M -0.12M -0.22M -0.55M -0.49M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Qrons Inc

Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. The company was incorporated in 2016 and is based in Long Island City, New York.

28-10 Jackson Avenue, Long Island City, NY, United States, 11101

212 945 2080

https://qrons.com

2

Name Title Year Born
Mr. Jonah Martin Meer Co-Founder, CEO, CFO, Sec. & Director 1955
Mr. Ido Merfeld Ph.D. Co-Founder, Pres & Director 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…